Becton, Dickinson and Company Investigation
The law firm of Kirby McInerney LLP is investigating potential claims against Becton, Dickinson and Company (“Becton” or the “Company”) (NYSE: BDX). This investigation concerns whether Becton has violated federal securities laws and/or engaged in other unlawful business practices.
On February 6, 2020, Becton lowered its fiscal 2020 guidance, expecting revenue to increase by only 1.5 to 2.5 percent, “to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.” According to the Company, the software remediation plan for the Alaris system “will require additional regulatory filings,” and existing customers would have “access to the Alaris System under medical necessity.”
On this news, Becton’s share price fell $33.74, or 11.8%, to close at $252.25 per share on February 6, 2020.
If you acquired Becton securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at firstname.lastname@example.org, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.